Navigation Links
Catalyst Biosciences Appoints Dr. Todd Lorenz Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Oct. 28 /PRNewswire/ -- Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase(TM) therapeutics, has appointed Todd Lorenz, M.D., as the company's Chief Medical Officer. Dr. Lorenz's career encompasses nearly 20 years of experience focused on the clinical development of novel medicines.

"We are excited to welcome Dr. Lorenz to the Catalyst team," said Nassim Usman, Ph.D., Chief Executive Officer of Catalyst Biosciences. "Hiring an experienced CMO to lead our development efforts is a critical step as Catalyst expands from drug discovery into clinical development. His expertise in clinical development and operations is particularly welcome as we advance our lead program, CB 813, an improved factor VIIa product for the treatment of acute bleeding in hemophiliacs, toward an IND filing in 2009."

"I am delighted to join Catalyst and have the opportunity to shape the clinical strategy for the company's pipeline of protease therapeutics," said Dr. Lorenz. "CB 813 is a highly promising compound with the potential to become a best-in-class therapeutic for hemophilia patients. Catalyst's protease therapeutics platform is poised to deliver a new class of biologics comparable in depth and scope to monoclonal antibodies."

Throughout his career, Dr. Lorenz has held leadership positions in the biotechnology and pharmaceutical industry with responsibilities across several therapeutic areas. Dr. Lorenz joins Catalyst from Johnson & Johnson (J&J), where he was Vice President and Associate Therapeutic Head for Cardiovascular Development. In this role, he contributed to clinical development efforts in several internal J&J entities including Scios, the Corporate Office of Science and Technology and Peninsula Pharmaceuticals. Dr. Lorenz served as Chief Medical Officer for Orexigen Therapeutics from 2005-2006 and was Chief Medical Officer at Corgentech from 2001-2005 where he was responsible for the clinical development of a transcription factor inhibitor through Phase 3 clinical development. From 1994-2001 at COR Therapeutics, Dr. Lorenz was intimately involved in the development, approval and medical affairs support for Integrilin(R), a novel platelet inhibitor, and from 1990-1994 he focused on the development of immunology product candidates at XOMA.

Dr. Lorenz is a graduate of Case Western Reserve University School of Medicine and trained in Internal Medicine at the University of Texas Southwestern. He completed a fellowship in Endocrinology and Metabolism at the University of California, San Francisco, and is board certified in both subspecialties. Dr. Lorenz has published extensively in journals such as Journal of the American Medical Association (JAMA), The Lancet, Circulation and the Annals of Thoracic Surgery.

About Catalyst Biosciences

Catalyst Biosciences is developing the next generation of biopharmaceuticals by harnessing the catalytic power of engineered proteases to target proteins underlying disease. Catalyst's discovery platform rapidly creates and optimizes tailor-made protease drug candidates that cleave a wide variety of disease targets, either by improving existing protease drugs or by creating new protease drugs, known as Alterase(TM) therapeutics. Initially, Catalyst is focusing its product development efforts on drug candidates for hemophilia, age-related macular degeneration, oncology and inflammation. To date, Catalyst has established two discovery research and product development agreements with Wyeth Pharmaceuticals and Centocor Research & Development, Inc. Catalyst is privately-held with backing by leading venture firms including Burrill & Company, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT BioVentures and Sofinnova Ventures. For more information, please visit

Catalyst Biosciences, Inc.

Erik Wiberg

Chief Financial Officer


BCC Partners for Catalyst Biosciences, Inc.

Karen L. Bergman or Michelle Corral

+1.650.575.1509 or +1.415.794.8662

SOURCE Catalyst Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
2. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
3. Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results
4. Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction
5. CATalyst Summit Declared a Success: Its All About the Cat!
6. Cardiva Medical, Inc. to Present Highlights of the Boomerang Catalyst(TM) II System at the Investment in Innovation (In3) West Conference on February 29, 2008 in Las Vegas, NV
7. Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance
8. Case in Point: Patient Control of Data Critical Catalyst for Online Health Care Revolution
9. Catalyst Pharmaceutical Partners, Inc. Set to Join Russell Microcap(R) Index
10. Congress Approves ePrescribing Initiative in Medicare Reform Bill: Critical Catalyst in Driving a New Generation of Prescribing
11. CATalyst Council Forms to Address Feline Health Care
Post Your Comments:
(Date:11/27/2015)... ... 2015 , ... The men and women on this list ... the country. They have overseen financial turnarounds, shown commitment to their community through ... as a whole through their advocacy and professional efforts. , Becker's Hospital Review ...
(Date:11/27/2015)... San Francisco, California (PRWEB) , ... November 27, 2015 , ... ... 1969 Janis Joplin Ann Arbor Michigan boxing style concert posters. This is one of ... 1969 at the Canterbury House at the University of Michigan in Ann Arbor. The ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point Recovery, ... together on Thanksgiving Day to share the things that they are most grateful ... Point YouTube channel, patients displayed what they wrote on index cards, describing the ...
(Date:11/26/2015)... ON and Cambridge, ON (PRWEB) , ... November ... ... today the availability of a real-time eReferral system for diagnostic imaging in the ... ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic medical ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug Delivery ... to integrate dose form selection in early phase drug development. The first of ... and bringing together the UK’s emerging life sciences companies, corporate partners, and investors, ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Research and Markets ( ) has announced the ... Type (Dressings, Therapy Devices, Active Wound Care), Application (Surgical ... Geography - Global Forecast to 2020" report to ... --> The purpose of this report is to ... advanced wound care market. It involves deep dive analysis ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> adds "Global ... and "Investigation Report on China Repaglinide ... 2021 forecasts data and information to ... . --> ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Italian therapeutic drug monitoring market, including ...
Breaking Medicine Technology: